Immuneering Corporation

https://www.immuneering.com

Twitter: @Immuneering

LinkedIn: https://www.linkedin.com/company/immuneering-corporation

Since its launch in February 2008, Immuneering has partnered with leading pharmaceutical companies to accelerate and improve the discovery and clinical development of novel drugs. The Immuneering team applies proprietary computational biology methods and an advanced drug discovery platform to high-throughput molecular data, re-engineering the process by which new medicines are discovered and developed to be faster, less expensive, and more likely to succeed. The company's proprietary drug discovery platform identifies "hits" (the molecular structures that form the basis of new medicines) in a matter of days or weeks, rather than the months or years of target identification and high-throughput screening typically required. This acceleration is made possible by applying artificial intelligence (AI) and other advanced algorithms to high-throughput data, and draws on Immuneering's decade of experience in applying high-throughput data to pharmaceutical R&D. Immuneering's team of experts also provides world-class bioinformatics and computational biology services. *

	Start	2008-02-01 established
	Industry	drug discovery software
	Industry 2	artificial intelligence (AI) / machine learning (ML)
	Person	Zeskind, Ben (Immuneering 201806 CEO)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	245 Main Street 2nd Floor
	City	02142 Cambridge, MA
		Address record changed: 2021-03-28

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Evotec AG. (11/21/18). "Press Release: Evotec and Immuneering to Collaborate on Artifical Intelligence (“AI”) Driven Ligand Identification for Rare Hereditary Metabolic Diseases". Hamburg & Cambridge, MA.

		Record changed: 2021-03-28